Skyline Biosciences
1 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| This Study is to Evaluate the Safety and Pharmacokinetics of SBS-101 in Patients With Oral Premalignant Lesions (NCT03939364) | Skyline Biosciences | 2022-01-01 |
Track Skyline Biosciences automatically
Every clearance here is in the API, with alerts when new ones post.